[2015 updated position statement of the management of hyperglycaemia in type 2 diabetes].
The strategy for the management ot type 2 diabetes, summarized by a group of European and American experts, has been updated early 2015. A patient-centered approach is recommended and the first drug choice is metformin combined with lifestyle improvement. After failure of metformin monotherapy, the selection of a second drug should be based on the efficacy, safety and cost of each pharmacological class. When compared to the position statement of 2012, the most important changes are the possible addition of a gliptin to a dual oral therapy or even to insulin, the commercialization of sodium-glucose cotransporters type 2 (SGLT2) inhibitors (gliflozins, to be used in dual or triple therapy, even in combination with insulin) and the possible combination of a glucagon-like peptide-I receptor agonist together with a basal insulin.
A J
AJ
Scheen
N
N
Paquot
D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy* / Q000209:etiology*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use; D017410:Practice Guidelines as Topic
D007004:Hypoglycemic Agents; D008687:Metformin